Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2008-12-10
pubmed:abstractText
Human semen contains peptides capable of forming amyloid fibrils termed semen-derived enhancer of viral infection (SEVI) that can greatly increase human immunodeficiency virus (HIV) infection. While SEVI appears to enhance virion attachment to target cells, its underlying mechanism of action is unknown. We now demonstrate that the intrinsic positive charges of SEVI (pI = 10.21) facilitate virion attachment to and fusion with target cells. A mutant form of SEVI in which lysines and arginines are replaced with alanines retains the ability to form amyloid fibrils but is defective in binding virions and enhancing infection. In addition, the interaction of wild-type SEVI with virions and the ability of these fibrils to increase infection are abrogated in the presence of various polyanionic compounds. These anionic polymers also decrease the enhancement of HIV infection mediated by semen. These findings suggest that SEVI enhances viral infection by serving as a polycationic bridge that neutralizes the negative charge repulsion that exists between HIV virions and target cells. Combinations of agents that neutrale SEVI action and produce HIV virucidal effects are an attractive future direction for microbicide development.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-10400729, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-11286708, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-12134048, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-12355096, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-14617360, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-14747357, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-16172109, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-16492075, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-17913809, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-18025873, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-18083097, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-1995952, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-7193233, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-9144379, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-9298697, http://linkedlifedata.com/resource/pubmed/commentcorrection/18945786-9352294
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1098-5514
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
83
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
73-80
pubmed:dateRevised
2010-9-22
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection.
pubmed:affiliation
Gladstone Institute of Virology and Immunology, University of California, P.O. Box 419100, San Francisco, CA 94141-9100, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural